A Self‐Adaptive Biomimetic Periosteum Employing Nitric Oxide Release for Augmenting Angiogenesis in Bone Defect Regeneration
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202302153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Zhangzhe Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China. Hauptthemen laut MEDLINE: Periosteum, Nitric Oxide. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Natural Science Research of Jiangsu Higher Education Institutions of China.
Abstract (Originalsprache)
The periosteum plays a vital role in the regeneration of critical‐size bone defects and highly comminuted fractures, promoting the differentiation of osteoblasts, accelerating the reconstruction of the vascular network, and guiding bone tissue regeneration. However, the materials loaded with exogenous growth factors are limited by the release and activity of the elements. Therefore, the material structure must be carefully designed for the periosteal function. Here, a self‐adaptive biomimetic periosteum strategy is proposed, which is a novel interpenetrating double network hydrogel consisting of diselenide‐containing gelatin and calcium alginate (modified natural collagen and polysaccharide) to enhance the stability, anti‐swelling, and delayed degradation of the hydrogel. The diselenide bond continuously releases nitric oxide (NO) by metabolizing endogenous nitrosated thiols (RSNO), activates the nitric oxide‐cycle guanosine monophosphate (NO‐cGMP) signal pathway, coordinates the coupling effect of angiogenesis and osteogenesis, and accelerates the repair of bone defects. This self‐adaptive biomimetic periosteum with the interpenetrating double network structure formed by the diselenide‐containing gelatin and calcium alginate has been proven to be safe and effective in repairing critical‐size bone defects and is expected to provide a promising strategy for solving clinical problems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China.
- Orthopaedic Institute, Medical College, Soochow University, Suzhou, 215007, China.
- Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, Department of Polymer Science and Engineering, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou,…
ORCID-Profile: Xuesong Zhu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Natural Science Research of Jiangsu Higher Education Institutions of China
- Gusu Innovation and Entrepreneur Leading Talents project
Zitieren
APA
Zhou, Z., Liu, Y., Li, W., Zhao, Z., Xia, X., Liu, J., Deng, Y., Wu, Y., Pan, X., He, F., Yang, H., Lu, W., Xu, Y., & Zhu, X. (2024). A Self‐Adaptive Biomimetic Periosteum Employing Nitric Oxide Release for Augmenting Angiogenesis in Bone Defect Regeneration. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202302153
Vancouver
Zhou Z, Liu Y, Li W, Zhao Z, Xia X, Liu J, et al. A Self‐Adaptive Biomimetic Periosteum Employing Nitric Oxide Release for Augmenting Angiogenesis in Bone Defect Regeneration. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202302153
BibTeX
@article{Zhou2024,
author = {Zhou, Zhangzhe and Liu, Yang and Li, Wenjing and Zhao, Zhijian and Xia, Xiaowei and Liu, Junlin and Deng, Yaoge and Wu, Yubin and Pan, Xiangqiang and He, Fan and Yang, Huilin and Lu, Weihong and Xu, Yong and Zhu, Xuesong},
title = {A Self‐Adaptive Biomimetic Periosteum Employing Nitric Oxide Release for Augmenting Angiogenesis in Bone Defect Regeneration},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202302153}
}
EUVIMED